EDIT-401 preclinical data shows ~90% mean reductions in LDL-C, Lp(a), ApoB in NHPs

Editas Medicine, Inc.

Single dose achieved ≥90% mean reduction in LDL-C, rapid and dose-dependent, durable through 6 months in NHPs.
Achieved ~90% mean reduction in Lp(a) and ApoB, supporting unified LDLR upregulation mechanism.
Well-tolerated at therapeutically relevant dose 1.5 mg/kg; no adverse observations in ongoing GLP toxicology.
Plans to submit CTN in Australia by mid-2026; first-in-human HeFH trial later in 2026; early human PoC data by end of 2026.
Received positive pre-IND feedback from FDA on nonclinical package, CMC plans, and study design.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.